Skip to main content
Publications
Winfree KB, Ainsworth C, Njue A , Molife C, Lyall M, Jen M-H, Bittoni M, Heyes A , Carbone DP. Defining aggressive disease in patients with advanced NSCLC receiving second-line treatment: a systematic review . Poster presented at the IASLC 19th World Conference on Lung Cancer; September 26, 2018. Toronto, Canada. [abstract] J Thorac Oncol. 2018 Oct; 13(10 (Suppl)):5908. doi: 10.1016/j.jtho.2018.08.1671
Samelson EJ, Miller PD, Christiansen C, Daizedeh NS, Grazette L, Anthony MS , Egbuna O, Wang A, Siddhanti SR, Cheung AM, Franchimont N, Kiel DP. RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk . J Bone Miner Res. 2014 Feb;29(2):450-7. doi: 10.1002/jbmr.2043
See CW, Srinivasan M, Saravanan S, Oldenburg CE, Esterberg EJ , Ray KJ, Glaser TS, Tu EY, Zegans ME, McLeod SD, Acharya NR, Lietman TM. Prior elicitation and Bayesian analysis of the Steroids for Corneal Ulcers Trial . Ophthalmic Epidemiol. 2012 Dec;19(6):407-13.